A revised electronic version of RUCAM for the diagnosis of DILI
- PMID: 35014066
- PMCID: PMC9233102
- DOI: 10.1002/hep.32327
A revised electronic version of RUCAM for the diagnosis of DILI
Abstract
Background and aims: Roussel Uclaf Causality Assessment Method (RUCAM) for DILI has been hindered by subjectivity and poor reliability. We sought to improve the RUCAM using data from the Drug-Induced Liver Injury Network (DILIN) and the Spanish DILI Registry, published literature, and iterative computer modeling.
Approach and results: RUCAM criteria were updated, clarified, and computerized. We removed criteria 3 (risk factors) for lack of added value and criteria 4 because we felt it more useful to assess each drug separately. Criteria 6 (drug-specific risk) was anchored to LiverTox likelihood scores. Iterative testing in subsets of 50-100 single-agent, nonherbal cases from both registries was done to optimize performance. We used classification tree analysis to establish diagnostic cutoffs for this revised electronic causality assessment method (RECAM) and compared RECAM with RUCAM for correlation with expert opinion diagnostic categories in 194 DILI cases (98 DILIN, 96 Spanish DILI). Area under receiver operator curves for identifying at least probable DILI were the same at 0.89 for RECAM and RUCAM. However, RECAM diagnostic categories have better observed overall agreement with expert opinion (0.62 vs. 0.56 weighted kappa, p = 0.14), and had better sensitivity to detect extreme diagnostic categories (73 vs. 54 for highly likely or high probable, p = 0.02; 65 vs. 48 for unlikely/excluded, p = 0.08) than RUCAM diagnostic categories.
Conclusions: RECAM is an evidence-based update that is at least as capable as RUCAM in diagnosing DILI compared with expert opinion but is better than RUCAM at the diagnostic extremes. RECAM's increased objectivity and clarity will improve precision, reliability, and standardization of DILI diagnosis, but further refinement and validation in other cohorts are needed.
© 2022 American Association for the Study of Liver Diseases.
Figures
Comment in
-
Digitizing DILI: Who can? RUCAM? RECAM?Hepatology. 2022 Jul;76(1):3-5. doi: 10.1002/hep.32312. Epub 2022 Jan 27. Hepatology. 2022. PMID: 34990036 No abstract available.
-
Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury.Hepatology. 2022 Oct;76(4):E71-E72. doi: 10.1002/hep.32522. Epub 2022 Jun 10. Hepatology. 2022. PMID: 35451140 No abstract available.
References
-
- Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323–30. - PubMed
-
- Chalasani NP, Maddur H, Russo MW, et al. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol 2021;116:878–898. - PubMed
-
- European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline Panel C, Panel m, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019;70:1222–1261. - PubMed
-
- Kaplowitz N Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308–10. - PubMed
-
- Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009;29:348–56. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK065211/DK/NIDDK NIH HHS/United States
- U24-DK065176/DK/NIDDK NIH HHS/United States
- UL1 RR025761/RR/NCRR NIH HHS/United States
- U01-DK082992/DK/NIDDK NIH HHS/United States
- U24 DK065176/DK/NIDDK NIH HHS/United States
- U01 DK083020/DK/NIDDK NIH HHS/United States
- U01 DK065238/DK/NIDDK NIH HHS/United States
- U01 DK065193/DK/NIDDK NIH HHS/United States
- U01 DK083023/DK/NIDDK NIH HHS/United States
- U01-DK100928/DK/NIDDK NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- U01-DK065201/DK/NIDDK NIH HHS/United States
- U01-DK065184/DK/NIDDK NIH HHS/United States
- U01 DK083027/DK/NIDDK NIH HHS/United States
- U01 DK065201/DK/NIDDK NIH HHS/United States
- U01 DK100928/DK/NIDDK NIH HHS/United States
- U01-DK083027/DK/NIDDK NIH HHS/United States
- U01-DK083020/DK/NIDDK NIH HHS/United States
- U01DK065193/DK/NIDDK NIH HHS/United States
- U01-DK083023/DK/NIDDK NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- U01- DK065211/DK/NIDDK NIH HHS/United States
- UL1 TR000083/TR/NCATS NIH HHS/United States
- U01-DK065238/DK/NIDDK NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- U01 DK065184/DK/NIDDK NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- U01 DK082992/DK/NIDDK NIH HHS/United States
